Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Total Current Liabilities came in at $54.9 billion in Q2 2026, up 1.32% year-over-year from $54.2 billion in Q2 2025, and down 4.89% quarter-over-quarter from $57.7 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Total Current Liabilities across 18 years of filings, most recently posting $54.9 billion for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 1.32% year-over-year to $54.9 billion; the TTM figure through Jun 2026 stood at $54.9 billion (up 1.32% YoY), while the FY2025 annual figure was $54.1 billion, up 7.56% from the prior year.
- Total Current Liabilities came in at $54.9 billion for Q2 2026 at Johnson & Johnson, down from $57.7 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $60.4 billion in Q2 2023 to a low of $43.4 billion in Q2 2022.
- Average Total Current Liabilities over 5 years is $51.2 billion, with a median of $51.8 billion recorded in 2024.
- Year-over-year, Total Current Liabilities soared 39.14% in 2023 and declined 19.29% in 2024.
- Over 5 years, Total Current Liabilities stood at $45.5 billion in 2022, then advanced by 1.62% to $46.3 billion in 2023, then climbed by 8.73% to $50.3 billion in 2024, then gained by 7.56% to $54.1 billion in 2025, then advanced by 1.42% to $54.9 billion in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $54.9 billion in Q2 2026, $57.7 billion in Q1 2026, and $54.1 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 32.65 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 37.11 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 354.06 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1.31 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Jazz Pharmaceuticals | 16.02 Bn | 14.40 Bn | 1.09 Bn | 2.23 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 54.90 Bn |
| Mar 29, 2026 | 57.72 Bn |
| Dec 28, 2025 | 54.13 Bn |
| Sep 28, 2025 | 50.87 Bn |
| Jun 29, 2025 | 54.18 Bn |
| Mar 30, 2025 | 56.90 Bn |
| Dec 29, 2024 | 50.32 Bn |
| Sep 29, 2024 | 51.76 Bn |
| Jun 30, 2024 | 53.93 Bn |
| Mar 31, 2024 | 48.73 Bn |
| Dec 31, 2023 | 46.28 Bn |
| Oct 1, 2023 | 44.37 Bn |
| Jul 2, 2023 | 54.17 Bn |
| Apr 2, 2023 | 60.37 Bn |
| Jan 1, 2023 | 55.80 Bn |
| Oct 2, 2022 | 45.54 Bn |
| Jul 3, 2022 | 44.82 Bn |
| Apr 3, 2022 | 43.39 Bn |
| Jan 2, 2022 | 45.23 Bn |
| Oct 3, 2021 | 44.56 Bn |